

CHRNB3 Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP20832c

Specification

CHRNB3 Antibody (Center) - Product Information

Application WB,E
Primary Accession O05901

Other Accession P12391, O8BMN3

Reactivity
Predicted
Host
Clonality
Isotype
Calculated MW
Antigen Region

Hamster
Mouse, Rat
Rabbit
Polyclonal
Rabbit IgG
52729
187-200

CHRNB3 Antibody (Center) - Additional Information

Gene ID 1142

Other Names

Neuronal acetylcholine receptor subunit beta-3, CHRNB3

Target/Specificity

This CHRNB3 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 187-200 amino acids from the Central region of human CHRNB3.

Dilution

WB~~1:1000

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CHRNB3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

CHRNB3 Antibody (Center) - Protein Information

Name CHRNB3 (HGNC:1963)



Function Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:11118490, PubMed:16835356, PubMed:35889515). Has an accessory rather than functional role and is only able to form functional nAChRs when co-assembled with another beta subunit (PubMed:11118490, PubMed:16835356). Participates in pentameric assemblies along with CHRNA3, CHRNA4, CHRNA6, CHRNB2 and CHRNB4 (PubMed:11118490, PubMed:16835356). Modulates receptor assembly and increases receptor sensitivity to nicotine when associated with CHRNB2, CHRNA4 and/or CHRNA6 as well as CHRNA3 and CHRNB4 (PubMed:11118490, PubMed:16835356). Seems to play a role in nicotine addiction (PubMed:11118490, PubMed:16835356).

Cellular Location


Synaptic cell membrane {ECO:0000250|UniProtKB:070174}; Multi-pass membrane protein. Cell membrane {ECO:0000250|UniProtKB:070174}; Multi-pass membrane protein

CHRNB3 Antibody (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture


CHRNB3 Antibody (Center) - Images



Western blot analysis of lysates from mouse heart, rat brain tissue (from left to right), using CHRNB3 Antibody (Center)(Cat. #AP20832c). AP20832c was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at



35ug per lane.



Western blot analysis of lysates from mouse heart, rat brain tissue lysate (from left to right), using CHRNB3 Antibody (Center)(Cat. #AP20832c). AP20832c was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 35ug per lane.

CHRNB3 Antibody (Center) - Background

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

CHRNB3 Antibody (Center) - References

Elliott K.J., et al.J. Mol. Neurosci. 7:217-228(1996). Groot Kormelink P.J., et al.FEBS Lett. 400:309-314(1997). Keddache M., et al.Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases. Willoughby J.J., et al.Neurosci. Lett. 155:136-139(1993).